That the judge accepted her operational role yet still released her suggests the balancing exercise turned on factors beyond the strength of the alleged conduct.
A British judge has ordered the extradition of Sukhjit Singh Ghuman, a 48-year-old British Indian businessman, to the United States to face charges connected to the import of unapproved cancer drugs and the fraudulent billing of American health insurers, the Times of India reports. The same ruling, according to the newspaper, discharged his former wife, Kiranjit Ghuman, also 48, despite the judge's finding that she played an active role in the alleged scheme.
The allegations, as set out in the report, are that the couple obtained cheap, unapproved chemotherapy drugs from India, Sri Lanka and Turkey and used them on cancer patients at oncology clinics they controlled in California and Arizona. The clinics then allegedly billed Medicare and other insurers as though more costly drugs approved by the US Food and Drug Administration had been administered, with the difference kept as profit. The report states that the couple fraudulently billed Medicare for more than $9.6 million.
District judge Nina Tempia rejected the argument that Kiranjit Ghuman's involvement was limited. The report says the judge noted that she controlled the Arizona and California clinics as senior vice-president of Colton Health, LLC, and that she played an active role in them. Even so, the judge discharged her, describing the case as one of the exceptional instances in which family life outweighs the public interest in extradition.
The ruling is a reminder of how differently the two sides of a single alleged conspiracy can be treated once the legal tests diverge. For Sukhjit Ghuman, the question before the court was whether the American case justified surrender; for his former wife, the court weighed the same allegations against the protections afforded to family life. That the judge accepted her operational role yet still released her suggests the balancing exercise turned on factors beyond the strength of the alleged conduct, though the report does not specify what those factors were.
The case also touches a wider concern in transatlantic health enforcement. The alleged route — unapproved medicines sourced from South Asia and Turkey, dispensed in American clinics, and billed to insurers at approved-drug prices — is the kind of arbitrage that regulators on both sides of the Atlantic have long sought to close. Extradition to the United States exposes a British resident to American sentencing practice, which is generally harsher than the British equivalent, and the order is therefore a significant moment for the defendant.
Several points remain unconfirmed. The report does not say whether Sukhjit Ghuman will appeal the order, whether the British home secretary must still approve the surrender, or when any transfer would take place. It gives no account of his response to the allegations, which remain untested in an American court, and no detail on the status of any co-defendants or on the clinics themselves. What is clear is that one half of the alleged scheme now faces the prospect of a US trial, while the other has been told, on family grounds, that she will not.


